



CRS 2022 Annual Meeting & Expo

Advanced Delivery Science

July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada



mRNA Nanomedicine
for Precision Cancer
Immunotherapy

Jinjun Shi

*Associate Professor
Center for Nanomedicine
Brigham and Women's Hospital
Harvard Medical School*




HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL



Mass General Brigham





Genetic Causes of Cancer




- ❖ Pro-tumorigenic drivers: many are considered 'difficult-to-drug'
- ❖ Tumor suppressors: deleted or mutated

Opportunities for RNA medicines

p53



PTEN



LETTER

Nature

doi:10.1038/nature13948

Convergent loss of *PTEN* leads to clinical resistance to a PI(3)K α inhibitor




CANCER DISCOVERY

Home About Articles For Authors Alerts News Search Q

Research Articles






Loss of *PTEN* Promotes Resistance to T Cell-Mediated Immunotherapy

Lipid-Polymer Hybrid mRNA NP Formulation





- Enhance cellular uptake and endosomal escape
- Prolong systemic circulation and improve tumor accumulation

PTEN Restoration for Treatment of *PTEN*-null Human PCa



Loss/Mutation of PTEN Is Correlated with Poor Immunotherapy







Hwu lab, Cancer Discov 2015; Futreal lab, Sci Transl Med 2017; Van Allen lab, Immunity 2017; Tolaney lab, Clin Cancer Res 2020





PTEN loss is associated with

- i) decreased T-cell infiltration at tumor sites*
- ii) increased expression of immunosuppressive cytokines*
- iii) poor-response or resistance to immune checkpoint blockade (e.g., anti-PD-1)*






PTEN Restoration Induces Immunogenic Cell Death (ICD)



PTEN Restoration Modulates the Immunosuppressive Tumor Microenvironment






PTEN mRNA NPs Improves anti-PD-1 Efficacy in s.c. Melanoma Model





Combination of p53 Restoration and ICB for HCC






- Anti-PD-L1 with anti-VEGF: first-line standard of care treatment for HCC
- Anti-PD-1 with anti-CTLA4: second-line for HCC



Combinatorial Treatment Reprograms the Immune Microenvironment



Synergistic Anti-Tumor Efficacy in HCC



Summary

- The lipid-polymer hybrid NPs were developed for systemic mRNA delivery to restore tumor suppressors (PTEN and p53).
- Restoration of PTEN induced anti-tumor immunity and improved the efficacy of immune checkpoint inhibitors (anti-PD-1).
- *Combination of p53 immune checkpoint inhibitors reprograms immune microenvironment for better HCC treatment.*
- The combination of p53 restoration and mTOR inhibition led to potent anti-tumor effect in p53-deficient HCC and NSCLC (*Sci Transl Med 2019*).
- *The NP co-delivery of mRNA antigen and TLR7/8 adjuvant elicits strong anti-tumor immunity (*Biomaterials 2021*).*



Acknowledgement

BCH / HMS

Bruce R. Zetter, Ph.D.

MGH / HMS

Dan G. Duda, D.M.D., Ph.D.

UMBC

Chuck Bieberich, Ph.D.

Team

Ariful Isam, Ph.D.

Yaoxin Lin, Ph.D.

Yi Wang

Na Kong

Yuling Xiao, Ph.D.

Xiangfei Han, Ph.D.

Weimin Tang, Ph.D.

Dean Chen

Kimia Abedi

Support

